Clobazam (oral Formulation)

# Clobazam (oral Formulation) ## Overview Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as an antiepileptic drug (AED) that can be used as adjunctive therapy. ## Primary Indications Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. ## Adult Dosing * **Initiation:** 5 mg twice daily. * **Titration:** Increase dose by 5-10 mg every week based on clinical response and tolerability. * **Maintenance:** Typically 10 mg to 20 mg twice daily. * **Maximum:** 40 mg per day. ## Pediatric Dosing (2 to 18 years) * **Initiation:** 2.5 mg twice daily. * **Titration:** Increase dose by 2.5 mg to 5 mg every week based on clinical response and tolerability. * **Maintenance:** Typically 10 mg twice daily. * **Maximum:** 20 mg per day for patients weighing less than 30 kg; 40 mg per day for patients weighing 30 kg or more. ## Dose Adjustments * **Hepatic Impairment:** Use with caution; no specific dosing adjustments are established, but lower doses may be warranted. * **Renal Impairment:** Use with caution; no specific dosing adjustments are established. ## Contraindications Known hypersensitivity to clobazam or other benzodiazepines. ## Adverse Effects Common: Somnolence, decreased appetite, constipation, lethargy, aggression, irritability, upper respiratory tract infection, drooling, vomiting, gait disturbance, ataxia, rash. Serious: Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior and ideation, withdrawal symptoms (seizures, rebound insomnia), respiratory depression, dependence and abuse potential. ## Key Drug Interactions * **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression. * **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam plasma concentrations. * **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam plasma concentrations. * **Phenytoin:** Clobazam can increase phenytoin levels. ## Monitoring * Monitor for efficacy (seizure frequency). * Monitor for adverse effects, particularly somnolence, behavioral changes, and skin reactions. * Monitor for signs of withdrawal upon discontinuation. * Consider therapeutic drug monitoring if efficacy or toxicity is suspected, though routine monitoring is not typically required. ## Clinical Pearls * Clobazam is a Schedule IV controlled substance. * Initiate and titrate slowly to minimize side effects. * Taper dose gradually upon discontinuation to avoid withdrawal symptoms. * Educate patients and caregivers about potential serious skin reactions and suicidal ideation. * Be aware of potential for drug interactions, especially with other CNS depressants and CYP2C19 modulators. *** **Disclaimer:** This information is intended for healthcare professionals and should not be a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for complete details before making any treatment decisions. Dosing may vary based on individual patient factors and local protocols.